Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity

Abstract

Purpose. Dose-rounding of chemotherapy is increasingly being used in oncology departments to improve the efficiency of outpatient clinics. There is, however, no published data on the effect of this strategy on drug toxicity.

Methods. We have analysed acute chemotherapy side effects in a cohort of 662 consecutive patients receiving adjuvant FEC (5-fluorouracil, epirubicin, cyclophosphamide) for breast cancer. A dose-rounding algorithm was used to deliver drug doses that were within 5% of the standard dose based on body surface area.

Results. Patients receiving a rounded dose of chemotherapy that was higher than that calculated from their body surface area were not at increased risk of acute haematological or non-haematological toxicity.

Conclusions. Dose-rounding of adjuvant FEC within the range ±5% is not associated with any difference in acute chemotherapy side effects. Longer term follow-up is required to determine whether patients receiving rounded doses below that calculated from their body surface area are at increased risk of relapse.

Keywords

dose-rounding chemotherapy breast cancer

Get full access to this article

View all access options for this article.

References

Plumridge R. , Sewell G. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am J Health-Syst Pharm 2001; 58: 1760-1764.

Kaestner S. , Sewell G. Chemotherapy Dosing Part II: Alternative approaches and future prospects. Clin Oncol 2007; 19: 99-107.

Dooley M. , Singh S. , Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Suppot Care Cancer 2004; 12: 653-656.

Baker J. , Jones S. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice 1998; 4: 10-14.

Jenkins P. , Elyan S. , Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007; 43: 544-548.

Mouridsen H. , Andersen J. , Andersson M. , Dombernowsky P. , Ejlertsen B. , Rose C. et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proceedings of Am Soc Clin Oncol 1999; 19: 68a (abstr 254).

DuBois D. , DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871.

Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-611.

Group FAS. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 599-601.

10.

Bonadonna G. , Valagussa P. , Moliterni A. , Zambetti M. , Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up . N Engl J Med 1995; 332: 901-6.